Sumithira Vasu1, Maria Berg2, Jan Davidson-Moncada3, Xin Tian4, Herb Cullis5, Richard W Childs6. 1. Division of Hematology, The Ohio State University, Columbus, Ohio, USA. 2. Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA. 3. Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA. 4. Office of Biostatistics Research, National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA. 5. American Flouroseal Corporation, Gaithersburg, Maryland, USA. 6. Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA. Electronic address: childsr@nhlbi.nih.gov.
Abstract
BACKGROUND AIMS: Umbilical cord blood transplantation (UCBT) is increasingly used to treat acute leukemias. UCB units are thawed and infused in their entirety at transplant, precluding later use as immunotherapy to prevent or treat leukemia relapse. METHODS: We developed a device that selectively thaws only 1 mL of the UCB unit, leaving the remaining UCB unit cryopreserved for subsequent transplantation. We also show that large numbers of CD56(+) natural killer (NK) cells can be expanded from these 1-mL fractions of selectively accessed UCB. Immunomagnetic depletion of CD3(+) cells of the 1-mL fraction was performed, and the cells were subsequently stimulated with irradiated Epstein-Barr virus-transformed lymphoblastoid cell lines (EBV-LCLs) and set to culture in media containing interleukin (IL)-2. RESULTS: When a 1:20 ratio of total nucleated cells to EBV-LCL feeder cells was used, day-21 and day-35 NK cell cultures initiated from 1 mL of UCB contained a median of 430 × 10(6) (range: 44-4321 × 10(6)) and 6092 × 10(6) (range: 165-20947 × 10(6)) CD3(-)CD56(+) NK cells. These cells expressed high levels of CD161, LFA-1, CD69, NKG2D, NKp30, NKp44, NKp80 and NKp46. UCB-derived NK cells were highly cytotoxic against K562 leukemia cells, although cytotoxicity was slightly lower than in expanded PBMC-derived NK cells. CONCLUSIONS: We have developed and optimized a strategy to selectively access a small fraction from cryopreserved UCB and show that large numbers of CD56(+) cells can be expanded from this selectively accessed fraction. This strategy presents a method to explore whether early adoptive transfer of NK cells expanded from the same UCB unit used for transplantation can prevent leukemic relapse and decrease graft-versus-host disease after UCBT. Published by Elsevier Inc.
BACKGROUND AIMS: Umbilical cord blood transplantation (UCBT) is increasingly used to treat acute leukemias. UCB units are thawed and infused in their entirety at transplant, precluding later use as immunotherapy to prevent or treat leukemia relapse. METHODS: We developed a device that selectively thaws only 1 mL of the UCB unit, leaving the remaining UCB unit cryopreserved for subsequent transplantation. We also show that large numbers of CD56(+) natural killer (NK) cells can be expanded from these 1-mL fractions of selectively accessed UCB. Immunomagnetic depletion of CD3(+) cells of the 1-mL fraction was performed, and the cells were subsequently stimulated with irradiated Epstein-Barr virus-transformed lymphoblastoid cell lines (EBV-LCLs) and set to culture in media containing interleukin (IL)-2. RESULTS: When a 1:20 ratio of total nucleated cells to EBV-LCL feeder cells was used, day-21 and day-35 NK cell cultures initiated from 1 mL of UCB contained a median of 430 × 10(6) (range: 44-4321 × 10(6)) and 6092 × 10(6) (range: 165-20947 × 10(6)) CD3(-)CD56(+) NK cells. These cells expressed high levels of CD161, LFA-1, CD69, NKG2D, NKp30, NKp44, NKp80 and NKp46. UCB-derived NK cells were highly cytotoxic against K562leukemia cells, although cytotoxicity was slightly lower than in expanded PBMC-derived NK cells. CONCLUSIONS: We have developed and optimized a strategy to selectively access a small fraction from cryopreserved UCB and show that large numbers of CD56(+) cells can be expanded from this selectively accessed fraction. This strategy presents a method to explore whether early adoptive transfer of NK cells expanded from the same UCB unit used for transplantation can prevent leukemic relapse and decrease graft-versus-host disease after UCBT. Published by Elsevier Inc.
Entities:
Keywords:
cryopreserved cord blood; expanded NK cells; ex vivo expansion; natural killer cells; umbilical cord blood
Authors: L Ruggeri; M Capanni; M Casucci; I Volpi; A Tosti; K Perruccio; E Urbani; R S Negrin; M F Martelli; A Velardi Journal: Blood Date: 1999-07-01 Impact factor: 22.113
Authors: John E Wagner; Juliet N Barker; Todd E DeFor; K Scott Baker; Bruce R Blazar; Cindy Eide; Anne Goldman; John Kersey; William Krivit; Margaret L MacMillan; Paul J Orchard; Charles Peters; Daniel J Weisdorf; Norma K C Ramsay; Stella M Davies Journal: Blood Date: 2002-09-01 Impact factor: 22.113
Authors: Juliet N Barker; Timothy P Krepski; Todd E DeFor; Stella M Davies; John E Wagner; Daniel J Weisdorf Journal: Biol Blood Marrow Transplant Date: 2002 Impact factor: 5.742
Authors: Veronika Bachanova; Dhifaf Sarhan; Todd E DeFor; Sarah Cooley; Angela Panoskaltsis-Mortari; Bruce R Blazar; Julie M Curtsinger; Linda Burns; Daniel J Weisdorf; Jeffrey S Miller Journal: Cancer Immunol Immunother Date: 2017-12-07 Impact factor: 6.968
Authors: Christian Chabannon; Bechara Mfarrej; Sophie Guia; Sophie Ugolini; Raynier Devillier; Didier Blaise; Eric Vivier; Boris Calmels Journal: Front Immunol Date: 2016-11-15 Impact factor: 7.561